Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages 394-402

  Miller, Paul D ^a   Wagman, Rachel B ^b,c   Peacock, Munro ^d   Lewiecki, E Michael ^e   Bolognese, Michael A ^f   Weinstein, Richard L ^g   Ding, Beiying ^b   San Martin, Javier ^b   McClung, Michael R ^h  

^a University of Colorado Health Sciences Center   (United States)

^b AMGEN INC   (United States)

^c STANFORD UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^f Bethesda Health Research   (United States)

^g Diablo Clinical Research   (United States)

^h OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; BACTERIAL INFECTION; BONE DENSITY; BONE DISEASE; BONE NECROSIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTACT DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIVERTICULITIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPEPSIA_DAVS ECZEMA; ENDOCARDITIS; FEMALE; FEMUR NECK; FRACTURE; FRACTURE NONUNION; GASTROESOPHAGEAL REFLUX; HEADACHE; HIP; HUMAN; HYPERTENSION; HYPOAESTHESIA; HYPOCALCEMIA; INFLUENZA; LIVER CANCER; LIVER DISEASE; LONG TERM CARE; LUMBAR SPINE; LUNG CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEOPLASM; OSTEOLYSIS; OSTEOPOROSIS; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; RADIUS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; STAPHYLOCOCCAL SKIN INFECTION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; FEMALE; HIP; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RADIUS; RANK LIGAND; SPINE;

EID: 79951689707     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1805     Document Type: Article

References (26)

1. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
2. Seeman E, DelmasPD2006 Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
3. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258 (Pubitemid 41094365)
4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett- Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082 (Pubitemid 29014065)
5. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, BlackDM2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289
6. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R 2009 Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24:1544-1551
7. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592 (Pubitemid 34615244)
8. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254 (Pubitemid 29268962)
9. Shih J, Bauer DC, Orloff J, Capizzi T, Thompson D, Oppenheimer L, Ross PD 2002 Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors. Osteoporos Int 13:S38-S39
10. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK 2009 Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182-195
11. Kostenuik PJ 2005 Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625 (Pubitemid 41614462)
12. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
13. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
14. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss StudyG2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222-229
15. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA 2007 Two-year treatment with denosumab(AMG162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22:1832-1841 (Pubitemid 351229299)
16. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
17. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
18. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199 (Pubitemid 38339363)
19. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462-468 (Pubitemid 40174503)
20. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR 2005 Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista(CORE)study. J Bone Miner Res 20:1514-1524 (Pubitemid 41243540)
21. Reid I, Miller P, Brown J, Kendler D, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese M, Woodson G, Bone H, Ding B, Wagman R, Martin JS, Ominsky M, Dempster D; Denosumab Phase 3 Bone Histology Study Group 2010 Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 35:2256-2265
22. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J 2010 Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. J Bone Miner Res 25:1886-1894
23. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153-161
24. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG 2010 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72-81
25. Frost HM 1987 The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents. Bone Miner 2:73-85 (Pubitemid 17119417)
26. Frost HM 1987 Bone "mass" and the "mechanostat": a proposal. Anat Rec 219:1-9